In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer buys Encysive for $191mm in cash

Executive Summary

In an effort to strengthen its portfolio of high blood pressure products, Pfizer is acquiring all outstanding shares of Encysive Pharmaceuticals for $2.35 each (a 185% premium to the 10-day average) in cash, a total of about $191mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register